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a b s t r a c t
The advent of modern molecular biology has allowed for the discovery of several mechanisms by which
oncoviruses promote carcinogenesis. Remarkably, nearly all human oncogenic viruses increase levels of the
transcription factor hypoxia-inducible factor 1 (HIF-1). In this review, we highlight HIF-1's signiﬁcance in
viral oncogenesis, while providing an in-depth analysis of its activation mechanisms by the following
oncoviruses: human papillomaviruses (HPVs), hepatitis B/C viruses (HBV/HCVs), Epstein–Barr virus (EBV),
Kaposi's sarcoma-associated herpes virus (KSHV), and human T-cell lymphotropic virus (HTLV-1). We
discuss virus-induced HIF-1's role in transcriptional upregulation of metabolic, angiogenic, and microenvir-
onmental factors that are integral for oncogenesis. Admittedly, conclusive evidence is lacking as to whether
activation of HIF-1 target genes is necessary for malignant transformation or merely a result thereof. In
addition, a complete understanding of host–virus interactions, the effect of viral genomic variation, and the
clinical (and potential therapeutic) relevance of HIF-1 in viral oncogenesis warrant further investigation.
& 2014 Elsevier Inc. All rights reserved.
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Introduction
Approximately 16% of yearly cancer diagnoses worldwide are
attributable to an infectious agent (de Martel et al., 2012). The fraction
of cancers linked to infection varies greatly by geographical location
and socioeconomic factors: while only 7.4% of cancer diagnoses are the
result of infection in developed countries, up to 22.9% of cancers in
developing parts of the world arise due to infection. In Sub-Saharan
Africa, a striking one-third of cancer diagnoses are the result of
infection (de Martel et al., 2012); the majority of these cancers are
the result of infection with an oncovirus. Thus, oncovirus-induced
cancers are an important global concern.
Oncoviruses contribute to carcinogenesis by altering the func-
tion of cellular targets that play pivotal roles in the development of
cancer. Over the past few decades, many of the cellular mechan-
isms by which oncoviruses induce malignant transformation have
been elucidated. One of the best-documented cases of oncogenic
viruses disrupting normal cellular functions involves the tumor
suppressor protein, p53. Several oncogenic viral proteins—such as
the E6 oncoprotein of high-risk human papillomavirus (HPV) types
and the HBx oncoprotein of hepatitis B virus (HBV)—have inhibi-
tory effects on the pro-apoptotic ability of p53. The high-risk HPVs
have additional cellular targets: the E6 oncoprotein increases
telomerase activity and the E7 oncoprotein degrades the retino-
blastoma tumor suppressor protein (Scheffner et al., 1993; Boyer
et al., 1996; Klingelhutz et al., 1996).
There is strong evidence that activation of the hypoxia-inducible
factor 1 (HIF-1) transcription factor is a common pathway affected
by human oncogenic viruses. HIF proteins are major components of
the innate hypoxic stress response in non-cancerous cells, acting as
transcription factors for a multitude of genes required for adaptation
under low oxygen conditions (Wang et al., 1995a). Three HIF isoforms
have been identiﬁed (i.e., HIF-1, HIF-2 and HIF-3), however research
to date has focused primarily on HIF-1. As such, this review will focus
on HIF-1, but HIF-2 and HIF-3 could be assessed in future studies of
viral carcinogenesis.
Transcriptionally active HIF-1 is a heterodimer made up of
α- and β-subunits (the β subunit is also known as aryl hydro-
carbon receptor nuclear translocator (ARNT), which also dimerizes
with several other transcription factor subunits). The dimer is a
member of the basic helix loop helix-PER-ARNT-SIM (bHLH-PAS)
family of transcription factors that play a role in cancer develop-
ment (Bersten et al., 2013). In normal, non-hypoxic cells, HIF-1α is
continually synthesized and degraded, while HIF-1β is constitutively
expressed to levels that remain relatively constant within the
nucleus (Fig. 1A). HIF-1 activity is largely dependent on the
regulation of its α subunit at several levels including transcription,
translation, ubiquitin-mediated protein breakdown, nuclear trans-
location, and association with transcriptional co-activators. HIF-1α
mRNA is ubiquitously expressed and its levels are similar for most
cell types studied between hypoxic and normoxic conditions
(Wenger et al., 1997). However, some cell types, such as hepato-
cellular carcinoma (HCC) Hep3B cells, exhibit an increase in HIF-1α
transcription under hypoxic conditions (Wang et al., 1995a). In vivo
investigations initially uncovered the potential for environmental
hypoxia inducing HIF-1α transcription (Wiener et al., 1996), but
Fig. 1. Regulation of HIF-1 protein levels. The level of HIF-1 in a given cell is subject to its oxygen-independent synthesis (A) and oxygen-dependent degradation (B). (A) The
synthesis of HIF-1α is augmented in an oxygen-independent manner by transcription factors acting on its upstream regulatory region (URR) and the PI3K/Akt and ERK/MAPK
pathways acting on its translation. When a growth factor binds to its respective tyrosine kinase receptor, PI3K (in the PI3K pathway) or RAS (in the ERK/MAPK pathway) is
activated. In the PI3K pathway, PI3K then activates Akt and subsequently mTOR. In the ERK/MAPK pathway, RAS activates RAF, which activates MEK and subsequently ERK.
ERK activates MNK that, together with mTOR, deactivates the 4E-BP, which allows for the formation of the eIF-4E complex. Along with p70S6K1, that is also activated by ERK,
eIF-4E enhances the translation of HIF-1α mRNA. (B) When oxygen is present, PHDs are active and hydroxylate HIF-1α at Pro-402 and/or Pro-564. HIF-1α-OH becomes
ubiquitinylated by VHL and subsequently broken down by the 26S proteasome. Conversely, under hypoxic conditions, PHDs cannot hydroxylate HIF-1α and it will accumulate
in the cytoplasm before translocating to the nucleus to complex with HIF-1β and p300/CBP to enhance target gene expression. A rectangular border represents nucleic acids
and circles are proteins. Black and white backgrounds represent speciﬁc HIF-1 and effector cellular components, respectively. The dotted line represents the nuclear
membrane. Refer to abbreviation list for full names.
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conﬂicting studies found no such effect (Wenger et al., 1996;
Stroka et al., 2001). More recent work has supported the notion
that hypoxia can inﬂuence HIF-1α transcription through inter-
mediate pathways (Sperandio et al., 2009; BelAiba et al., 2007).
Alternatively, analysis of the promoter and 50-UTR of the HIF-1α
gene revealed putative binding sites of several transcription
factors in this region including speciﬁcity protein (SP-1), activator
protein (AP-1), nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-κB) and HIF-1 itself (Minet et al., 1999). Recent
studies found that enhancing NF-κB and signal transducer and
activator of transcription 3 (STAT-3) increase the transcription of
HIF-1α (van Uden et al., 2008; Rius et al., 2008; Niu et al., 2008).
While HIF-1α transcription is continual, several growth factors
and their associated pathways play a role in enhancing HIF-1α
signaling in an oxygen-independent manner by augmenting the
translation of HIF-1α mRNA. In the phosphatidylinositol-3-kinase
(PI3K) pathway, binding of a growth factor (e.g., insulin-like
growth factor 1) to its cognate tyrosine kinase receptor (RTK)
results in phosphorylation of PI3K, which in turn, activates the
serine/threonine kinase, Akt (an action that can be inhibited by the
tumor suppressor, PTEN), and subsequently phosphorylates mam-
malian target of rapamycin (mTOR) (Semenza, 2003). Additionally,
growth factors can act on the mitogen-activated protein kinase
(MAPK) pathway such that MAPK kinase (MEK) is activated by RAF
and goes on to phosphorylate MAPK (ERK). Activated ERK is then
capable of phosphorylating p70S6K1, which is required for trans-
lation of HIF-1α mRNA. In addition to activation of p70S6K1, ERK
also activates MAPK-interacting protein (MNK) that functions to
activate the translation initiator, elF-4E together with mTOR by
inhibiting the 4E binding protein (4E-BP) (Agani and Jiang, 2013).
In this fashion, the PI3K and MAPK pathways collectively function
to initiate HIF-1α protein synthesis in an oxygen-independent
manner (Fig. 1A).
The majority of work surrounding HIF-1 regulation has been on
its constitutive normoxic protein breakdown. HIF-1α degradation
is initiated by hydroxylation at one of its proline residues (Pro-402
and/or Pro-564) by prolyl hydroxylases (PHD-1, PHD-2, and PHD-
3) that use molecular oxygen as a co-substrate (Bruick and
McKnight, 2001; Semenza, 2001). Upon hydroxylation, HIF-1α-
OH becomes ubiquitinylated by the von Hippel Lindau E3 ubiquitin
ligase protein (VHL), and subsequent proteasomal breakdown
occurs. When there is a lack of oxygen, PHDs cannot function,
resulting in stabilization of HIF-1α in the cytoplasm. Once HIF-1α
accumulates in the cytoplasm it may translocate to the nucleus by
way of α/β importins that requires a nuclear localization signal
(NLS) sequence in HIF-1α's C-terminus transactivation domain
(Depping et al., 2008). Once in the nucleus, HIF-1α may dimerize
with HIF-1β followed by HIF-1 complexing with the transcrip-
tional co-activators p300/CBP. Several studies have found that
phosphorylation of HIF-1α by way of the MAPK pathways enhance
stability and may also be required for transactivation (Richard
et al., 1999; Suzuki et al., 2001; Liu et al., 2003) in addition to other
posttranslational modiﬁcations that alter HIF-1 function including
acetylation (Lim et al., 2010) and small ubiquitin-like modiﬁer
(SUMO)ylation (Cheng et al., 2007). Furthermore, complex forma-
tion is inhibited under hypoxic conditions by the hydroxylase,
factor inhibiting HIF-1 (FIH-1). Similar to the PHDs, FIH-1 hydro-
xylates the transactivation domain of HIF-1α at Asn-803, which
inhibits the binding of the heterodimer HIF-1 to its transcriptional
coactivator p300 (Lando et al., 2002). If each of these HIF-1-
regulatory checkpoints are overcome in a given cell, activated HIF-
1 binds to hypoxia response elements (HREs) in target gene
promoters, transcriptionally activating a multitude of genes with
speciﬁc roles in the hypoxic response (Fig. 1B). Soon after the
seminal discovery of HIF-1 by Semenza and colleagues in the early
1990s, it was found that its overexpression was common in a
variety of cancers (Zhong et al., 1999; Krieg et al., 2000). Moreover,
increased HIF-1 has been associated with an unfavorable prog-
nosis in most cancers, as it activates genes that play a role in
promoting cancer metabolism, angiogenesis, invasion, and metas-
tasis (Semenza, 2003, 2010, 2012). Originally, this increase of HIF-
1α in cancers was primarily attributed to stabilization by environ-
mental hypoxia or genetic mutations (e.g., to VHL) in the pathways
leading to the destruction of HIF-1α (Semenza, 2003). However,
it has now become clear that most, if not all, human oncogenic
viruses directly enhance HIF-1, through various mechanisms
affecting its activity. Thus, HIF-1 represents a common pathway
affected by these genetically unrelated viruses.
In this review, we will outline the current understanding of the
mechanisms by which oncogenic viruses promote HIF-1 activity,
provide evidence for HIF-1's activation by oncoviruses in the
upregulation of key downstream target genes involved in cancer
progression, and highlight the activation of this pathway as a
unifying event in viral-induced malignant transformation.
Oncogenic viruses enhance HIF-1α levels by modulating its
transcription, translation, or stabilization
The inhibition of HIF-1α's transcriptional activity in non-
cancerous, normoxic cells, involves several processes—obstruction
of any one of the sequential steps in HIF-1α destruction can lead
to incomplete HIF-1α breakdown and subsequent activation of
downstream genes. Furthermore, it appears as though an increase
in HIF-1α mRNA translation via the PI3K/Akt/mTOR or MAPK
signaling pathways can also lead to an increase in activation of
target genes, such that the rate of proteasomal breakdown by the
oxygen-dependent pathway of HIF-1α is insufﬁcient to inhibit its
transcriptional activity (Jiang et al., 2001; Laughner et al., 2001).
It is obvious that there exist multiple ways by which HIF-1 activity
can be increased; each one of these pathways can potentially be
targeted by oncogenic viruses for production of gene products
conducive to cancer cell growth and spread (Tables 1 and 2 and
Fig. 2). Whatever path may be taken, it is clear that six of the seven
known oncogenic viruses have a component in their infectious
arsenal that results in HIF-1 activity.
The human papillomaviruses
Human papillomaviruses (HPVs) were ﬁrst described in the
mid-1980s as a causative agent of cervical cancer (zur Hausen,
2002), which could be either malignant (high-risk types) or benign
(low-risk types). Several putative cellular targets of the two HPV
oncogenes (E6 and E7) have been characterized, including p53,
pRb (reviewed in Wise-Draper and Wells, 2007), and more
recently, HIF-1. The ﬁrst evidence of HPV inducing HIF-1 activity
came from in vivo studies of K14-HPV16 transgenic mice which
harbor the entire early region of HPV16 under the control of the
basal keratin 14 promoter. The authors reported an upregulation of
HIF-1α and its target mRNAs during epidermal carcinogenesis
(Elson et al., 2000). The use of an in vivo model provided a context
reminiscent of HPV infection where early genes are expressed in
basal keratinocytes. However, in this particular study, quantiﬁca-
tion of viral gene expression and protein levels were not assessed
for their correlation with the HIF-1 pathway. The authors con-
tinued these in vivo studies further characterizing the role of HIF-1
in cervical carcinogenesis (Lu et al., 2007). Along with these in vivo
assessments of the role of HIF-1 in HPV16 carcinogenesis, both the
E6 and E7 oncogenes of high risk HPVs have been scrutinized for
their ability to induce HIF-1 transcriptional activity.
The E6 oncogene has many well-studied cellular functions,
including the proteasomal breakdown of p53 via the E3 ubiquitin
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Table 1
Mechanisms of oncoviral induced HIF-1α enhancement (by virus).
Oncovirus
(type)
Associated
cancer(s)
Viral protein(s) Cellular target(s) Mechanism/context Reference
HPV
(dsDNA)
Ano-genital,
HNSCC, Others
Early region N/A HPV16 transgenic mice have higher levels of HIF-1α and target mRNAs Elson et al. (2000)
E6 p53 E6-mediated p53 degradation enhances HIF-1α stability Ravi et al. (2000)
E6, E7, whole
genome
N/A Hypoxia mimetic DFO treatment enhances HIF-1α stability in cells transfected with whole genome or transduced
with E6 and E7 either separately or together
Nakamura et al.
(2009)
E7 HDAC1, 4, 7 E7 binds to HDACs that associate with HIF-1α, enhancing transcription complex formation Bodily et al. (2011)
HBV
(dsDNA-RT)
HCC HBx ERK1/2 MAPK pathway The MAPK pathway enhances the protein synthesis of HIF-1α independent of oxygen levels Yoo et al. (2003)
HIF-1α Binding by the C-terminus of HBx interferes with PHD/VHL-mediated HIF-1α protein degradation Yoo et al. (2004)
Moon et al. (2004)
HDAC1 Enhancing HDAC1 transcription leads to increased deacetylation of the ODD of HIF-1α, inhibiting its degradation Yoo et al. (2008)
HCV
(ssRNA)
HCC Subegenomic
replicon
region of HCV
genotype 2a
PI3K/Akt, ERK1/2 MAPK,
STAT-3, NF-ĸB pathways
HCV infected Huh-7 cells indirectly activate several kinase pathways acting on HIF-1α by increasing intracellular
oxidative stress
Nasimuzzaman
et al. (2007)
Core NF-ĸB HCV Core protein enhances NF-ĸB signaling leading to HIF-1α mRNA transcription Abe et al. (2012)
EBV
(dsDNA)
Lymphomas, NPC LMP-1 ERK1/2 MAPK pathway LMP-1 enhances the rate of protein synthesis of HIF-1α by enhancing ERK1/2 MAPK signaling Wakisaka et al.
(2004)
PHD-1, LMP-1 upregulates Siah-1, an E3 ubiquitin ligase that targets PHD-1 and PHD-3 for breakdown Kondo et al.
(2006)PHD-3
EBNA-1 Activation of the AP-1
transcription factor
EBNA-1 enhances the transcription of the HIF-1α gene, potentially by increasing the activity of AP-1, O’Neil et al.
(2008)
EBNA-5, PHD-1, EBNA-3 and EBNA-5 bind to PHD-1 and PHD-2, respectively, inhibiting the breakdown of HIF-1α via the oxygen-
dependent pathway
Darekar et al.
(2012)EBNA-3 PHD-2
KSHV
(dsDNA)
Kaposi’s Sarcoma vGPCR ERK1/2 and p38 MAPK
pathways
ERK1/2 and p38 MAPK both act as independent pathways in the phosphorylation (activation) of HIF-1α Sodhi et al. (2000)
PI3K/Akt, ERK1/2, p38,
IKKβ
vGPCR expressing endothelial cells secrete cytokines acting on several pathways enhancing the synthesis of HIF-1α Jham et al. (2011)
LANA-2/vIRF-3 HIF-1α vIRF3 binds directly to HIF-1α, leading to an increase in nuclear translocation and activity Shin et al. (2008)
LANA1 VHL LANA1 functions as part of the EC5S ubiquitin complex to degrade VHL Cai et al. (2006a)
HTLV-1
(ssRNA-RT)
T-Cell Leukemia Tax PI3K/Akt pathway Under normoxic conditions, HTLV-1 infected cell lines had high levels of HIF-1α Tomita et al.
(2007)
Abbreviations: HNSCC, head and neck squamous cell carcinoma; HCC, hepatocellular carcinoma; NPC, nasopharyngeal carcinoma; ODD, oxygen-dependent domain; see text for full names of abbreviated viruses, viral proteins, and
cellular targets.
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ligase, E6-Associated Protein (E6-AP). The p53 tumor suppressor
protein binds to and induces HIF-1α degradation thus the pre-
sence of E6 induces an increase in HIF-1α under hypoxic condi-
tions (Ravi et al., 2000). In their study, Ravi and colleagues
conﬁrmed that transfection of PA-1 ovarian teratocarcinoma cells
with the high-risk HPV E6 oncogene boosts HIF-1α stability under
hypoxic (1% O2) culture conditions. While this study shows that
E6-mediated p53 breakdown enhances HIF-1α, it is not clear
whether or not this is reminiscent of an HPV infection as only E6
was introduced and levels of it's DNA copy number, mRNA and
protein expression were not assessed. Although E6 was introduced
into atypical host cells, the study set the stage for the investigation
of HPV and HIF-1α in normal keratinocytes.
The cell cycle progression-altering E7 oncogene of both high-
risk (type 16, 18, 31) and low-risk (type 11) HPV increases HIF-1
activity in the presence of several histone deacetylases (HDACs) by
binding to HIF-1α directly (Bodily et al., 2011). The binding of E7 to
HIF-1α was directly inhibited through deletion of the N-terminus
pRb binding domain of E7. Many HDACs (including HDAC1, 4, and
7) enhance HIF-1 activity on their own (Kato et al., 2004; Qian
et al., 2006; Yoo et al., 2006), however the authors hypothesized
that binding of HPV E7 to HIF-1α allows for the displacement of
these HDAC's from HIF-1α, permitting formation of the HIF-1
transcription complex, leading to downstream activation of target
genes. Previously, under conditions mimicking hypoxia, cells
treated with the hypoxic mimetic, deferoxamine, plus high-risk
HPV E7 or E6 exhibited higher protein levels of HIF-1α in
comparison to non-transduced keratinocytes under the same
conditions (Nakamura et al., 2009). The authors also looked at
whole genome transfection of high risk (HPV31) and low risk
(HPV11) viruses and found that HIF-1α protein levels were
enhanced under hypoxic conditions. However, a full evaluation
of viral mRNA and protein expression was not included. Thus, the
magnitude of viral gene expression required for an observed
increase in HIF-1α protein under these conditions by HPV is not
conclusive. These ﬁndings held true for HPV16 E6 and E7 under
normoxic conditions when transfected into HeLa (HPV18þ) and
C33A (HPV-) cervical cancer cell lines (Tang et al., 2007). Future
studies regarding the effect of HPV on the HIF-1 pathway are
warranted in order to establish a quantiﬁable relationship between
HPV expression and HIF-1 activity.
The hepatitis viruses
Infection with either hepatitis B (HBV) or C (HCV) induces
severe liver cirrhosis and inﬂammation as seen in more than 80%
of HCC patients (El-Serag, 2012). Like the papillomaviruses, these
two hepatitis viruses have carcinogenic properties that act on key
cellular targets involved in apoptosis and promotion of the cell
cycle during cancer progression (reviewed in: McGivern and
Lemon, 2011; Fallot et al., 2012; Arzumanyan et al., 2013). Both
hepatitis viruses have also been studied for their effect on the
HIF-1 pathway and its role in HCC progression. As stated previously,
HIF-1 activity can be induced through disruption to its oxygen-
dependent degradation, as well as by the oxygen-independent
increase in growth factor signaling. The latter mechanism appears
to occur in HBV-induced HCCs.
The major factor in the development of HCC induced by HBV
is the HBx gene (Kim et al., 1991; Benn and Schneider, 1995; Fallot
et al., 2012). In addition to inﬂicting genetic instability and
disrupting normal cell cycle control, the HBx protein (expressed
by inducible Chang liver cells) independently increases the trans-
lation of HIF-1α mRNA leading to an increase in its transcriptional
activity on target genes (Yoo et al., 2003). This HIF-1α activation by
HBx occurs via increased signaling of the MAPK pathway. Although
the study provided a qualitative assessment of HBx protein byTa
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western blot, quantiﬁcation was not performed. Measurement of
induced HBx mRNA expression was also not reported. In addition
to enhancing HIF-1α synthesis, its stabilization was also increased
in HBx transfected liver and non-liver cells, by introducing terminal
truncations to HBx to determine the speciﬁc binding region. This
stabilization was accomplished solely by the C-terminus of HBx
directly binding to the C-terminus to HIF-1α, potentially interfering
with its association with PHDs or VHL (Yoo et al., 2004). A concurrent,
but separate study found direct binding between full length HBx and
HIF-1α leading to stabilization of HIF-1α by inhibiting its interaction
with VHL (Moon et al., 2004).
HBx can also indirectly cause a rise in HIF-1 via a signaling
pathway containing the growth factor receptor, human epidermal
growth factor receptor-2 (HER2, also known as ErbB2). Retroviral
transduction of the HepG2 cell line with HBx leads to a transcrip-
tional upregulation of ERBB2, and corresponding increase in its
protein level (Liu et al., 2009). Enhanced ERBB2 signaling then
leads to higher HIF-1α levels through enhanced protein synthesis
via the PI3K/Akt pathway (Laughner et al., 2001). Increased Akt
phosphorylation has been reported in HBx transduced HepG2
cells, potentially leading to downstream enhancement of HIF-1α
synthesis, although in this paper, the authors did not report data
on HIF-1α activity (Liu et al., 2009). Collectively, these studies
imply that the HBx protein increases HIF-1α activity through both
inhibition of its oxygen-dependent degradation pathway, as well
as through ampliﬁcation of its synthesis through the MAPK path-
way. Lastly, HBx has also been implicated in the upregulation of
HIF-1 signaling by inducing the transcription of HDAC1 and
metastasis-associated protein 1 (MTA1) leading to an increase in
protein levels in vitro and in vivo (liver tissue of HBx-transgenic
mice), which stabilizes HIF-1 under hypoxic conditions by inhibit-
ing its association with PHDs and VHL (Yoo et al., 2008). While
these results at ﬁrst glance appear to be in conﬂict with those
involving HPV E7 and HDACs, it is possible that enhancement
of HDAC1 transcription by HBx inhibits HIF-1α degradation,
while binding of HPV E7 to HDACs augments its ability to
form transcriptional complexes—this remains to be conﬁrmed
experimentally. Thus, the key oncogenic protein of HBV has
acquired several mechanisms leading to upregulation of HIF-1α,
which likely accounts for its signiﬁcant association with the
development and progression of HCCs.
Hepatitis C virus has also independently acquired its own
mechanisms to increase HIF-1α. The ﬁrst evidence of HIF-1α
modulation by HCV came in 2007 when Nasimuzzaman and
colleagues showed that HCV's non-structural proteins were cap-
able of inducing HIF-1α protein levels, even under normoxic
conditions (Nasimuzzaman et al., 2007). Mechanistically, HCV
infection induces oxidative stress, which in turn, activates several
kinase pathways (Wang et al., 1998), including the PI3K and MEK
pathways that lead to increased HIF-1α synthesis (Tardif et al.,
2005; Nasimuzzaman et al., 2007). Treatment of HCV-infected HCC
Huh-7 cells with MEK and PI3K inhibitors was sufﬁcient to
completely block the induction of HIF-1α. Although the authors
used a liver-derived cell line, it would have been interesting to
observe the effect of HCV-infection on normal hepatocytes, since
HCC Huh-7 cells may already have altered pathways connected to
HIF-1. In addition to the non-structural proteins, the HCV Core
protein can independently induce HIF-1α and promote HCC (Ray
et al., 1997; Moriya et al., 1998). Under hypoxic conditions, stable
transfection with the HCV Core protein (but not the non-structural
protein NS5A or an empty vector) augmented HIF-1α by tran-
scriptionally upregulating HIF-1α mRNA via activation of the
NF-kB signaling pathway through an undetermined mechanism
(Abe et al., 2012). However, these results were found in HAK-1A
hepatoma cells already containing HCV, so it is unclear how
relevant this overexpression of Core is in relation to a natural
HCV infection.
The oncogenic herpes viruses
Of the nine distinct human herpes virus (HHV) types known
to cause disease, only the γ-herpes viruses—HHV-4 (Epstein–Barr
virus or EBV) and HHV-8 (Kaposi's sarcoma-associated herpes
virus or KSHV)—are oncogenic, and both are frequently found to
Fig. 2. Oncoviruses function to enhance HIF-1 transcriptional activity. Infection with an oncovirus in its respective target cells allows for the expression of speciﬁc
oncoproteins that lead to HIF-1α accumulation, followed by translocation to the nucleus. Here, it forms a complex with HIF-1β and p300/CBP that can then bind to HRE’s in
the promoters of and ampliﬁes their expression. Viral proteins are color coded for their respective virus shown at top: HPV (red), HCV (yellow), HBV (blue), EBV (green),
KSHV (pink), HTLV-1 (teal). Refer to abbreviation list for full names. A rectangular border represents nucleic acids and ellipses are proteins. Black and white backgrounds
represent speciﬁc HIF-1 and effector cellular components, respectively. The dotted line represents the nuclear membrane.
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cause cancers in immunocompromised individuals (Ramos da
Silva and Elgui de Oliveira, 2011). EBV infections promote several
cancers, including Burkitt's lymphoma, Hodgkin's disease, non-
Hodgkin's lymphoma, and nasopharyngeal carcinoma (Thompson
and Kurzrock, 2004). KSHV is a causative agent of Kaposi’s
sarcoma and primary effusion lymphoma—two cancers that are
associated with HIV infection (Wen and Damania, 2010). Each of
these two oncogenic herpes viruses are also capable of increasing
HIF-1α levels.
EBV primarily infects B cells of the immune system and can
transform them to latently infected lymphoblastoid cell lines (LCL)
in vitro. This occurs upon expression of a distinct repertoire of
latent viral proteins known as the EBV nuclear antigens (EBNAs)
and latent membrane proteins (LMPs) (Young and Rickinson,
2004; Kalla and Hammerschmidt, 2012). EBV’s contribution to
HIF-1 activity was ﬁrst noted when LCLs of Type II and Type III
latency expressing LMP-1 showed increased HIF-1α protein levels
over HeLa control cells under normoxic conditions (Wakisaka
et al., 2004). Furthermore, stable or transient transfection of the
nasopharyngeal carcinoma cell line Ad-AH with LMP-1 lead to a
signiﬁcant increase in HIF-1α protein levels as well as nuclear
translocation and transcriptional activity as measured by a lucifer-
ase assay of the VEGF promoter containing an HRE. The underlying
mechanism of LMP-1-induced HIF-1α protein level increase was
determined to be solely due to an increase in its mRNA translation,
rather than transcription, by activation of the p42/p44 MAPK
pathway, but not of the p38 MAPK pathway (Wakisaka et al., 2004).
While the classical MEK/MAPK pathway is typically associated with
promoting cell division and proliferation in response to growth
factor stimulation, the p38/MAPK pathway is known, along with
the JNK/MAPK pathway, to respond to inﬂammatory stresses
and elicit apoptosis and cell cycle arrest in a variety of cell types
(for review of mammalian MAPK pathways, see Qi and Elion,
2005). In LMP-1-transfected Ad-AH cells, HIF-1α accumulation
occurs via LMP-1’s effect on increasing production of reactive
oxygen species (ROS), particularly H2O2. This oxidative stress
activates MAPK signaling (Chandel et al., 2000; Son et al., 2011).
Increased signaling along the p42/p44 MAPK pathways upon EBV
LMP-1 transfection leading to HIF-1 activation could be the result
of a direct LMP-1-induced increase in H2O2 levels. In addition to
enhancing the synthesis of HIF-1α, the same group later found
that LMP-1 also functions to inhibit the degradation of HIF-1α by
increasing the level of Siah-1 protein, a key E3 ubiquitin ligase that
can induce the degradation of the PHDs required for HIF-1α
breakdown (Kondo et al., 2006). LMP-1 activation of Siah-1 was
regulated at the protein level through inhibiting its breakdown.
However, the precise mechanism of inhibiting Siah-1 breakdown
by LMP-1 was not determined. This is the ﬁrst evidence of an
oncogenic viral protein interfering with the oxygen-dependent
degradation of HIF-1α by inhibiting PHD activity, and provides a
novel mechanism for HIF-1 activation to be explored in other
cancers, particularly those of exogenous origin.
Several nuclear antigen proteins of EBV also function to
increase HIF-1α. EBNA-1 enhances the transcriptional activity of
activator protein 1 (AP-1), a transcription factor that targets the
HIF-1α gene. Evidently, stable transfection of EBNA-1 into Ad-AH
cells acts to initiate the transcription of HIF-1α (O’Neil et al., 2008).
However, whether the enhanced transcription of HIF-1α was
mediated solely by the AP-1 transcription factor was not deter-
mined. Two other nuclear antigen proteins act to interfere with
the degradation pathway of HIF-1α. As described previously, the
oxygen-dependent degradation of HIF-1α requires the activity of
PHD-1, PHD-2, and PHD-3 to hydroxylate HIF-1α, which is then
ubiquitinylated by VHL and degraded by the 26S proteasome.
Recent work illustrates that infection of full length EBV increases
HIF-1α protein levels and translocation to the nucleus in
comparison to normal cytokine-induced proliferating B cells.
Levels of HIF-1α mRNA, however, were in fact lower in newly
infected EBV cells and LCL’s in comparison to cytokine-induced
proliferating B cells, indicating that HIF-1α protein expression
alterations were post-transcriptional and that EBV infection
directly results in an HIF-1α increase, rather than resulting from
proliferation (Darekar et al., 2012). Two EBV nuclear antigen
proteins, EBNA-3 and EBNA-5, bind directly to PHD-2 and PHD-1,
respectively. In glutathione S-transferase pull-down assays of LCLs
binding of the EBV nuclear antigens to their appropriate PHD
binding partner leads to a concomitant increase in HIF-1α levels
within the nucleus, where it can form a heterodimer with HIF-1β
and activates the transcription of several target genes.
The second of the two oncogenic herpes viruses, KSHV, causes
Kaposi’s sarcoma, a cancer highly prevalent in immunosuppressed
individuals (Mesri et al., 2010). The genome of KSHV is relatively
large in comparison to other oncogenic viruses (e.g., approximately
170 kilobase pairs for KSHV vs. 8 kilobase pairs for HPV), and
contains over 80 open reading frames (ORFs) (Russo et al., 1996).
The 74th ORF of the genome encodes a KSHV viral G-protein
coupled receptor (vGPCR) (Bais et al., 1998, 2003; Montaner et al.,
2001). Stable transfection of vGPCR into NIH 3T3 mouse ﬁbroblast
cells results in activation of MEK and p38 signaling cascades,
leading to direct phosphorylation of HIF-1α, and thus subsequent
increases in HIF-1 transcriptional activity (Sodhi et al., 2000). The
activation of these two MAPK pathways is diminished in a dose-
dependent manner by MEK/MAPK and MMK6/p38 pharmacologi-
cal inhibitors in the vGPCR cells, with a correlative decrease in
transcription of HIF-1 target genes. While this study shows that
vGPCR, a report on the level of vGPCR mRNA or protein was not
included. As well, given the shear number of ORFs in KSHV,
studying vGPCR alone may be missing the full complexity of KSHV
and its affect on the HIF-1 pathway. In a separate study, vGPCR-
expressing cells were found to secrete cytokines that act on
neighboring cells in a paracrine fashion to induce HIF-1 and HIF-
2 through the Akt, ERK, p38, and inhibitor of nuclear factor kappa-
B kinase subunit beta (IKKβ) pathways, that in turn enhance
mTOR-mediated HIF upregulation (Jham et al., 2011). Blocking
the synthesis of HIF-1α using digoxin inhibited the in vivo tumori-
genic ability of vGPCR, again indicating that the viral activation of
HIF-1 enhances carcinogenesis. Furthermore, the latent nuclear
antigen-2 (LANA-2) gene of KSHV, also known as viral interferon
regulatory factor 3 (vIRF-3), is implicated in the stabilization of
HIF-1α, in addition to its oncogenic role of p53 inhibition (Rivas
et al., 2001). While no differences in mRNA levels were reported,
HIF-1α stability was enhanced by LANA-2/vIRF-3 when trans-
fected in SLK endothelial cells (Shin et al., 2008). Under normoxic
conditions, LANA-2/vIRF-3 binds to the bHLH domain of HIF-1α
and inhibits the breakdown of HIF-1α, which seemingly does not
have an impact on its dimerization capability, and only further
enhances the nuclear localization and transcriptional activity of
HIF-1. Although it is now known that LANA-2/vIRF-3 stabilizes
HIF-1α leading to its increased transcriptional activity, the
exact mechanism of how this occurs remains to be elucidated.
Additionally, considering vIRF3 is speciﬁcally expressed in host B
cells and associated with primary effusion lymphoma (PEL) (Rivas
et al., 2001), its effect on the HIF-1 pathway in endothelial cells
may not be congruent in a B cell environment.
The LANA-1 protein of KSHV plays a key role in KSHV’s
oncogenicity, as it has pRb inhibiting capacity coincident with
the ability to obstruct p53 activity (Friborg et al., 1999; Radkov
et al., 2000). Like LANA-2/vIRF-3 and vGPCR, which can enhance
HIF-1 activity under normoxic conditions, LANA-1 also has HIF-1
regulating properties. While LANA-2/vIRF-3 increases HIF-1α
activity by binding directly to it, LANA-1 further augments HIF-
1α stabilization in KSHV-transfected B cells by degrading VHL in
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the EC5S ubiquitin complex (Cai et al., 2006a). While cotransfec-
tion experiments showed HIF-1α to be enhanced by LANA-1, no
comment on endogenous levels of HIF-1 was made until a follow
up study where the same group found that HIF-1α protein
levels are higher in KSHV-positive PEL lines in comparison to
KSHV-negative cell lines, and LANA-1 stimulates the nuclear
accumulation of HIF-1α (Cai et al., 2007). RNA interference was
used to show that a decrease in LANA-1 was coincident with a
decrease in HIF-1α protein levels. The speciﬁc regions required for
the enhanced nuclear translocation of HIF-1α by LANA-1 were
determined to be their oxygen-dependent domain (ODD), and
the N-terminus amino acids 46–89, respectively. Lastly, there
appears to be a role for KSHV in enhancing the transcription of
HIF-1α mRNA in endothelial cells (Carroll et al., 2006). Clearly, the
KSHV virus has adopted numerous distinct mechanisms that
activate hypoxic signaling in infected cells, even under normoxic
conditions.
Interestingly, promoters of key KSHV genes have been found
to contain HREs (Haque et al., 2003), and activation of HIF-1α
transcriptional activity by LANA-1 leads to expression of these
lytic-reactivating genes (Cai et al., 2006b). It appears that LANA-1,
LANA-2/vIRF-3, and vGPCR enhance HIF1 activity, which in turn
induces lytic KSHV genes containing HREs, transitioning the virus
from its latent to lytic replication stage.
The human T-cell lymphotropic virus
The human T-cell lymphotropic virus-1 (HTLV-1) is the only
retrovirus known to be capable of directly causing cancer (adult
T-cell lymphomas or leukemias) in humans (Moore and Chang,
2010). The HTLV-1 Tax protein is critical for the virus’ ability to
transform and immortalize T cells (Grassmann et al., 2005). The
Tax protein is responsible for the activation of several oncogenic
signaling pathways, including the PI3K/Akt pathway (Peloponese
and Jeang, 2006; Jeong et al., 2008). In a robust study by Tomita
and colleagues, HIF-1α protein levels were increased even under
normoxic conditions in HTLV-1 positive cell lines in comparison to
proliferating T-cell leukemia cell lines not infected with HTLV-1
due to Tax’s effect of enhancing PI3K/Akt signaling (Tomita et al.,
2007). Mutants of Tax that were unable to activate PI3K/Akt
showed HIF-1 transcriptional activity comparable with untrans-
fected controls. Pharmacological inhibition of the PI3K/Akt path-
way showed a dose-dependent decrease in HIF-1 activity seen
upon wild-type Tax transfection. Levels of HIF-1α mRNA levels
were found to be comparable between both uninfected and HTLV-
infected leukemia lines, meaning that the augmentation of HIF-1α
protein levels lies solely in post-transcriptional alterations. The
proliferation of these cell lines appear directly affected by Tax-
induced HIF-1 activity, as knockdown of HIF-1α by way of siRNA
signiﬁcantly decreased the growth rate of HTLV-1 infected leuke-
mia cell lines. This is yet another conﬁrmation that activation of
HIF-1α by oncogenic viruses is a key pathway conferring enhanced
proliferation, likely by targeting key downstream targets involved
in cancer progression.
Downstream activation of genes involved in virally-induced
cancer progression by HIF-1
Metabolism
In normal, differentiated cells, glucose is metabolized to pyr-
uvate, followed by oxidative phosphorylation in order to maximize
adenosine triphosphate (ATP) as a cellular energy source, however
cancer cells exhibit glucose metabolism resembling that of anae-
robic cells (Vander Heiden et al., 2009). Under aerobic conditions,
pyruvate is converted to acetyl-CoA, which subsequently enters
the mitochondrial tricarboxylic acid (TCA) cycle, the products of
which (NADH, FADH2) donate electrons to the protein complexes
of the electron transport chain, generating a proton gradient
across the inner mitochondrial membrane. Relying on the pre-
sence of molecular oxygen as a ﬁnal electron acceptor, protons are
subsequently transported from the inter-membrane space into the
mitochondrial matrix via ATP synthase, which synthesizes ATP
from ADP and inorganic phosphate (Schultz and Chan, 2001).
Under hypoxic conditions, however, molecular oxygen is not
available as a ﬁnal electron acceptor, so pyruvate is not converted
to acetyl-CoA and subsequent oxidative phosphorylation does not
occur. Rather, pyruvate is converted to lactate by the ubiquitous
enzyme, lactate dehydrogenase, a process largely governed by
activation of HIF-1 and subsequent adaptive gene expression
(Semenza, 2000). It is precisely this hypoxic-like metabolism,
with lactate as the major byproduct, that cancer cells perform,
even in the presence of adequate oxygen—this phenomenon was
ﬁrst described by famed German physiologist, Otto Warburg, in the
1920s and thus termed theWarburg effect (Warburg et al., 1927; Shaw,
2006). It is generally thought that the Warburg effect is a requirement
for immortalization andmalignant transformation of cells, likely due to
the reduction in senescence-inducing ROS (e.g., H2O2, O2) that arise
from a primarily glycolytic mechanism of ATP production, as well as
permitting adaptation to the hypoxic environment typical of tumors
(Brand and Hermﬁsse, 1997; Kondoh et al., 2005; Kim and Dang, 2006;
Dolado et al., 2007).
Recent evidence has shown that upon infection of certain host
target cells, oncoviruses induce molecular changes that account for
a Warburg effect (Noch and Khalili, 2012). In some instances, these
metabolic changes are induced following acute infection with an
oncovirus (i.e., prior to the formation of a detectable tumor).
Therefore, it is likely that the induction of the Warburg effect,
either directly or indirectly, confers a proliferative advantage for
infected cells and is a necessary step to cancer. Among the genes
that are activated by HIF-1 and involve the Warburg effect are
those constituting a transition from oxidative phosphorylation
to predominately aerobic glycolysis. Metabolic gene targets of
HIF-1 have been known for years and it is clear that the enzymes
catalyzing glucose metabolism—phosphoglycerate kinase 1 (PGK1),
hexokinase 1 and 2 (HK1/2), glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), phosphofructokinase (PFK), and the glucose trans-
porters (GLUT-1, GLUT-3)—are upregulated by HIF-1 (Iyer et al., 1998).
Furthermore, key enzymes that contribute to the Warburg effect,
such as PDK1 and LDHA, are also HIF-1 targets (Semenza et al.,
1994; Lu et al., 2002; Kim and Dang, 2006; Semenza, 2007).
Due to HIF-1’s effect on metabolism, it is not surprising that an
increase in lactate production (i.e., Warburg effect) coincides with
HIF-1α upregulation by oncoviruses. Early histopathological stu-
dies of HPV16 transgenic mice reported a concomitant increase in
the mRNA levels of GLUT-1, PGK-1, and HIF-1α in basal keratino-
cytes during epidermal carcinogenesis (Elson et al., 2000). Simi-
larly, in EBV-infected LCL cells, EBNA proteins that bind to key PHD
proteins (involved in HIF-1α’s oxygen dependent degradation)
showed a signiﬁcant increase in metabolic enzymes (approxi-
mately 5, 4.5, 3.25, 6.5, and 2 fold increase for PGK1, GAPDH,
LDHA, GLUT-1, PDK1, respectively), along with an increase in
aerobic glycolysis (i.e., pyruvate and lactate acid production)
(Darekar et al., 2012). HCV viral protein expression has been
shown to increase HIF-1α levels in osteosarcoma cells transfected
with HCV genes, as well as the transcription of glycolytic enzyme
genes and other HIF-1α target genes. These observations coincide
with a decrease in oxidative metabolism, forcing ATP production
to occur largely via non-oxidative glycolytic metabolism, a HIF-1
controlled 2–2.5-fold transcriptional increase of the glycolytic
genes, LDHA and HK1 (Ripoli et al., 2010). These observations
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translate in vivo, where biopsies of HCV-positive hepatocellular
carcinomas show a signiﬁcant increase in HIF-1α and HK1 mRNA
over controls. Levels of LDHA mRNA were found to be higher as
well, albeit not signiﬁcantly (Ripoli et al., 2010). These in vivo
results are in agreement with recent studies showing that HCV
Core protein transcriptionally upregulates HIF-1α mRNA (Abe
et al., 2012). Other independent studies on the temporal proteome
of HCV-infected Huh-7.5 cells found changes consistent with a
shift from oxidative metabolism toward aerobic glycolysis, as
evidenced by increases in several metabolic HIF-1 targets that
are markers of the Warburg Effect upon acute HCV infection
(Diamond et al., 2010). Whether these increases in marker protein
levels correlate with a biologically relevant alteration in glucose
metabolism by HIF-1 remains to be determined.
In discussions of tumor metabolism, two schools of thought
exist. Some contend that HIF-1 induction of the Warburg effect in
cancer cells is simply the result of the hypoxic tumor microenvir-
onment (Garber, 2004). Others argue that the activation of the
Warburg effect by HIF-1 is an intrinsic mechanism cancer cells
have in order to ensure survival and continued proliferation upon
exposure to impending tumor hypoxia, and that without the
preceding activation of HIF-1, tumor formation would not be
feasible (Garber, 2004). Central to the latter contention is the fact
that many pathways (e.g., the PI3K & MAPK pathways) that are often
dysregulated in cancer have an impact on both HIF-1 activity and
other pathways involved in cancer progression. As described above,
cancers of exogenous origin have (often several) hard-wired mechan-
isms to increase HIF-1α levels. This supports the notion that HIF-1 is
an important factor in permitting initial tumor formation, perhaps by
allowing for adaptation to the ensuing hypoxic microenvironment
typical of most solid tumors. Some of these HIF-1-inducing oncov-
iruses cause systemic cancers (e.g., EBV and HTLV-1 induction of
B- and T-cell lymphomas, respectively). In such cases where environ-
mental hypoxia in tumor formation is not a characteristic, HIF-1 is
likely a key player in the malignant transformation pathway, and not
simply a consequence of hypoxia.
Angiogenesis
As with normal tissues, tumors require a constant supply of
nutrients that are obtained through the vasculature to ensure cell
survival and permit proliferation. To ensure these demands of the
rapidly proliferating cells are met, tumors have mechanisms to
ensure the formation of blood vessels through angiogenesis
(Hanahan and Weinberg, 2011; Carmeliet and Jain, 2011). New
blood vessels in the microenvironment are formed by enhancing
pro-angiogenic or by inhibiting anti-angiogenic factors. Perhaps
the most studied of the tumor angiogenic factors are those of the
vascular endothelial growth factor (VEGF) family, which is also a
transcriptional target of HIF-1 (Forsythe et al., 1996). In fact, we
have already discussed several studies containing reports of HIF-1
transcriptional activity based on its ability to activate VEGF-A
expression that, in turn, induces angiogenesis via the VEGF
receptor-2 (Carmeliet and Jain, 2011). In this section, we will focus
on each oncogenic virus’ contribution to angiogenesis via HIF-1.
The oncogenes of HPV have been examined for their ability to
induce VEGF expression and angiogenesis via the HIF-1 pathway.
The in vitro activation of HIF-1α via E6-induced p53 degradation
signiﬁcantly increases expression of a VEGF reporter gene contain-
ing the promoter region of VEGF (which also contains a HIF-1 HRE)
(Ravi et al., 2000). Additionally, in non-small cell lung cancer cells,
the overexpression of both HPV16 E6 and E7 oncoproteins is
associated with the promotion of angiogenesis both in vitro and
in vivo, and is due to enhanced HIF-1α, as well as downstream
VEGF mRNA and protein expression (Li et al., 2011). These studies
align with others that have found high-risk HPV oncoproteins
capable of inducing pro-angiogenic factors that are transcriptional
targets of HIF-1 (Le Buanec et al., 1999; Bequet-Romero and López-
Ocejo, 2000; López-Ocejo et al., 2000). Not surprisingly, pathology
studies reveal a similar trend—expression of multiple VEGF isoforms
are signiﬁcantly increased coincidently with the grade of cervical
intraepithelial neoplasia (Branca et al., 2006; Baritaki et al., 2007).
These reports agree with the mechanistic ﬁndings previously
described, wherein both E6 and E7 oncoproteins of high-risk HPV
have been found to directly activate HIF-1. Thus, E6 and E7 are likely
major factors contributing to VEGF induction, in addition to the
development of a hypoxic tumor microenvironment.
Angiogenic factors have also been studied in the context of
hepatitis viruses. Both HCV and HBV upregulate VEGF expression
through HIF-1. In the case of HCV-positive HCC, several markers of
angiogenesis have been found in vivo to be upregulated, notably
VEGF-A (Salcedo et al., 2005; Mas et al., 2007). Moreover, VEGF-A
was found to be expressed to signiﬁcantly higher levels in HCV-
HCC than in pre-malignant HCV-induced liver cirrhosis, due to
VEGF’s importance in cancer development and progression.
Experimental in vitro studies have conﬁrmed these ﬁndings: VEGF
expression follows the increase of HIF-1α that occurs from
enhanced HIF-1α synthesis via oxygen-independent pathways
(Nasimuzzaman et al., 2007). Soon after reports of HBV increasing
both HIF-1α translation via the MAPK pathway and VEGF angio-
genic signaling (Lee et al., 2000), it was also revealed that HBx
binds to HIF-1α and induces VEGF expression (Moon et al., 2004).
Recent work has implicated the mTOR pathway in VEGF produc-
tion in HCC by induction of the inﬂammatory tumor necrosis
factor (TNF)-α signaling pathway. A downstream kinase of the
TNF-α pathway, the β subunit of the IKKβ, activates mTOR
signaling via repression of the TSC1/TSC2 tumor suppressor
complex, which in turn leads to enhanced angiogenesis (Lee
et al., 2007). Whether or not the mechanism of IKKβ-induced
angiogenesis is HIF-1-mediated VEGF transcriptional upregulation
remains to be determined, but it is highly likely to at least be a
contributing factor, as enhanced mTOR signaling clearly augments
HIF-1 protein synthesis (Majumder et al., 2004; Thomas et al.,
2005; Demidenko and Blagosklonny, 2011), and environmental
hypoxia has shown a similar effect on VEGF signaling via mTOR
(Humar et al., 2002). Interestingly, the HBx oncoprotein also
activates mTOR signaling and VEGF-A angiogenesis through induc-
tion of IKKβ, and activation of key modulators in this pathway is
correlated with poor prognosis (Yen et al., 2012). Again, it remains
to be determined if this activation of angiogenic induction requires
HIF-1. The exact mechanism of IKKβ upregulation by HBx remains
to be elucidated but represents a possible novel pathway of
angiogenic signaling (potentially through HIF-1 induction) in
cancers arising from viral infection.
Given the promotion of angiogenesis by papillomaviruses and
hepatitis viruses through HIF-1, it is not surprising that EBV and
KSHV also induce VEGF expression in a similar manner. Several
studies of EBV viral proteins that contribute to HIF-1 induction have
included analyses of HIF-1-mediated VEGF upregulation. Following
early studies that alluded to EBV enhancing VEGF expression
(Murono et al., 2001; Krishna et al., 2006; Hui et al., 2002), each
of LMP-1 (Wakisaka et al., 2004) and EBNA-1 (O’Neil et al., 2008),
when studied for their HIF-1 induction capacity, presented
increases in VEGF production. Similarly, while trying to determine
the molecular underpinnings and the importance of angiogenesis
in Kaposi’s sarcoma (Cornali et al., 1996; Masood et al., 1997; Bais
et al., 1998), HIF-1α was shown to be activated by KSHV’s vGPCR
by pathways acting on the mTOR complex that lead to VEGF
production. In separate studies, the MAPK and p38 pathways
(Sodhi et al., 2000), as well the paracrine activation of Akt, ERK,
p38 and IKKβ on mTOR (Jham et al., 2011) result in VEGF induction
by this oncogenic virus. In studies using VEGF itself or its promoter
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(as a proxy of HIF-1 activity), LANA-1 (Cai et al., 2007) and LANA-
2/vIRF-3 (Shin et al., 2008), through the induction of HIF-1, lead to
transcriptional accumulation of VEGF. Lastly, these results are
mirrored with regard to human T-cell lymphotropic virus, where
HIF-1α levels are increased via activation of the PI3K/Akt pathway,
with a concomitant increase in VEGF mRNA (Tomita et al., 2007).
Invasion and metastasis
It is well documented that metastasis is responsible for up to
90% of cancer deaths, however, researchers are still unraveling the
complex mechanisms that contribute to its promotion. Following the
discovery that HIF-1 activation is common in cancer (Zhong et al.,
1999), it was promptly shown that it not only contributes to metabolic
reprogramming and angiogenesis, but also to metastatic potential by
transcriptionally activating several genes that promote invasiveness
(Krishnamachary et al., 2003; Semenza, 2003; Fujiwara et al., 2007).
Consequently, several of the key genes involved in amplifying meta-
static potential have also been found to be upregulated in both solid
and systemic malignancies of viral origin by altering cell adhesion and
motility as well as the tumor microenvironment.
Cell adhesion and motility
The downregulation of the epithelial adhesion molecule, E-cad-
herin, is a common characteristic of carcinomas that promotes
invasion (Schipper et al., 1991; Oka et al., 1993; Umbas et al., 1994;
Onder et al., 2008; Ma et al., 2010). E-cadherin repression allows
for epithelial–mesenchymal transition (EMT)—an event required
for proper embryonic development but also commonly observed
with carcinoma metastasis (Chua et al., 2006; Christiansen and
Rajasekaran, 2006; Acloque et al., 2008). Hypoxia can act as a
stressor for EMT activation via HIF-1 (Higgins et al., 2007), because
several genes that are E-cadherin repressors and involved in
embryonic development, such as Snail and Twist, are HIF-1 targets
(reviewed in Yang and Wu, 2008). A comprehensive study on HCC
found a signiﬁcant correlation of Snail and Twist induction in
promoting EMT and metastasis, particularly for HBV- and HCV-
positive samples (Yang et al., 2009). Following this report, in vitro
studies indicated that HCV glycoproteins E1 and E2 can contribute
to cancer cell migration through the upregulation of Snail and
Twist, by virtue of an HIF-1-dependent mechanism (Wilson et al.,
2012). Similarly, the LMP-1 protein of EBV that can enhance HIF-
1α levels via mTOR signaling (Wakisaka et al., 2004) also increases
Twist (Horikawa et al., 2007) and Snail (Horikawa et al., 2011)
expression. Each of these studies found the upregulation of Snail
and Twist to inversely correlate with E-cadherin levels and
associate with clinical metastases for nasopharyngeal carcinoma
(Horikawa et al., 2007, 2011). Following reports of HPV16 E6’s
ability to inhibit E-cadherin levels (Matthews et al., 2003), similar
results to those of hepatitis and Epstein–Barr viruses have been
found, where Snail, Twist and/or other E-cadherin repressors that
are targets of HIF-1 are upregulated by infection with HPV (Lee
et al., 2008; D’Costa et al., 2012). Complementary ﬁndings have
been reported for KSHV as well, where an endothelial-to-
mesenchymal transition is observed (Gasperini et al., 2012).
Whether or not these results are, in part, mitigated by their
respective viral oncoproteins’ effect on HIF-1 described previously
remains to be determined.
The microenvironment
Research over the past few decades has highlighted the
importance of the tumor microenvironment and its associated
components in promoting invasion into the bloodstream and
subsequent colonization at distant sites. These metastatic-
promoting factors may originate from tumor cells themselves or
from the very cells of the tumor microenvironment itself (e.g.,
tumor-associated macrophages) (environmental factors driving
cancer cell metastasis reviewed in: Steeg, 2006; Joyce and Pollard,
2009). One particular environmental factor driving cancer cell
metastasis and inﬂuenced by HIF-1 is pH. The HIF-1-induced War-
burg effect results in a signiﬁcant increase in lactic acid production,
and thus, a requirement for tumor cells to combat a decrease in pH in
order to survive. It is not surprising then, that HIF-1 upregulates
several pH-regulating membrane transporters, such as a lactate
transporter (monocarboxylate transporter 4) and carbonic anhydrase
IX and XII (CAIX/XII) (Parks et al., 2013). While CAIX is often simply
used as a hypoxic marker, it also correlates with advanced cancer
progression and poor overall survival (Bui et al., 2003; Swinson et al.,
2003; Potter and Harris, 2004). Of particular interest is CAIX’s role in
counteracting intracellular tumor acidosis (i.e., Warburg effect) by
catalyzing the reversible hydration of carbon dioxide, accounting for
reports of an observable decrease in extracellular pH, while con-
tributing to tumor growth (Švastová et al., 2004; Chiche et al., 2009).
Recent work has provided evidence of enhanced cancer metastasis
under acidic conditions and tumor growth being directed to sites of
low pH, indicating that the acidic microenvironment is a key aspect
of extracellular matrix remodeling (Estrella et al., 2013). Furthermore,
treatment with NaHCO3 as pH buffer signiﬁcantly increases the pH of
the tumor microenvironment, while decreasing metastases (Robey
et al., 2009; Estrella et al., 2013). These results may explain additional
roles of HIF-1 in enhancing tumor metastases and invasion, via the
upregulation of CAIX.
Several tumor viruses have been documented to enhance CAIX
expression, often concomitantly with HIF-1 activity increases.
The cervical carcinoma cell lines, SiHa and CaSki, which harbor
integrated HPV16, have been found to overexpress CAIX (Lee et al.,
2008). CAIX expression is further augmented (Niccoli et al., 2012)
by aggressive HPV16 E6 variants, such that the Asian-American E6
variant (Zehbe et al., 1998), which is found eight times more often
in invasive cervical cancer than prototype E6, relative to non-
cancer controls (Berumen et al., 2001). Thus, CAIX likely represents
a key protein in tumor microenvironment hypoxia, and in promot-
ing invasion. Similar results have been reported for the HBx
protein of HBV: transient transfection of Hep G2 cells with HBx
leads to an increase in CAIX mRNA expression and protein level via
HIF-1 (Holotnakova et al., 2010). Clinical specimens of nasophar-
yngeal carcinoma, an epithelial cancer for which infection with
EBV is a signiﬁcant risk factor (Lo et al., 1999; zur Hausen et al.,
1970), have been found to exhibit increased expression of HIF-1α
and CAIX, and the presence of the latter signiﬁcantly correlates
negatively with progression-free survival (Hui et al., 2002).
As mentioned, the upregulation of CAIX by HIF-1 is associated
with a decrease in extracellular pH (Chiche et al., 2009), which
likely provides an optimal environment of matrix remodeling
proteases (such as cathepsins and metalloproteases), as they
have been found to have highest activity in an acidic milieu
(Buck et al., 1992; Turk et al., 2001; Rofstad et al., 2006). Matrix
metalloprotease-2 (MMP-2) and MMP-9 are two more of the many
HIF-1 targets involved in promotion of angiogenesis and invasion
through proteolytic cleavage of extracellular matrix components
(Semenza, 2003; Choi et al., 2011). Indeed, either one or both of
these MMPs have been found to have increased expression and/or
activation of their respective zymogens by oncoviruses including,
HPV16 (Coussens et al., 2000; Cardeal et al., 2006), EBV (Yoshizaki
et al., 1998; Horikawa et al., 2000), HCV (Lichtinghagen et al.,
2003; Núñez et al., 2004), HBV (Kuo et al., 2000; Chung et al.,
2004; Liu et al., 2010), and KSHV (Wang et al., 2004; Qian
et al., 2007). It is worth noting that few studies have reported
whether or not activation of these MMPs was directly due to viral
genes’ activation of HIF-1—this remains a subject of future
exploration. However, some studies have documented that the
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role of the upstream signaling pathways that enhance HIF-1
activity (described earlier) are required for activation of the MMPs
under investigation (Chung et al., 2004) and several of the viral
oncogenes (such as LMP-1 of EBV) required for target cell trans-
formation and HIF-1, also induce MMP expression (Wakisaka and
Pagano, 2003).
Several additional genes involved in the invasion and metastasis
cascade, such as cathepsin D and urokinase plasminogen activator
receptor, among others, are targets of HIF-1 (Semenza, 2003).
Whether or not these and other genes involved in metastasis are
also activated by HIF-1 in oncoviral cancers has not yet been resolved
and remains an attractive area for future work, given the exhaustive
evidence for oncoviral HIF-1 activation.
Conclusion and future directions
Following the discovery by Gregg Semenza and colleagues in
the mid-1990s that HIF-1 is a key regulator of oxygen homeostasis
and adaptation to hypoxia came a plethora of studies elucidating
its importance in a variety of health conditions, including cardio-
vascular disease and cancer. With regard to cancer, HIF-1 is well
known to transcriptionally activate genes involved in metabolism,
angiogenesis and invasion/metastasis, as it is typically induced
within the tumour microenvironment that is notoriously hypoxic.
Thus, HIF-1 and its associated mechanisms of upregulation repre-
sent an attractive target in the ﬁght against malignancies with
detrimental prognoses.
In this review, we have exempliﬁed a unifying theme and the
mechanisms therein of viral oncogenes in the activation of HIF-1.
Key downstream target genes of HIF-1, including those of meta-
bolism and those that collectively promote proliferation and
metastases, have been reviewed in order to accentuate this path-
way in viral carcinogenesis. Most of the oncoviruses that have
been linked to human cancers have been clearly documented to
increase HIF-1 activity, which generally correlates with a poor
prognosis. A recently classiﬁed oncogenic virus, Merkel cell poly-
omavirus (MCV) (Feng et al., 2008), is associated with aggressive
carcinomas. Although one study has found inconsistent HIF-1α
staining in Merkel cell carcinomas (Fernández-Figueras et al.,
2006), further investigation is required to determine if there is a
relationship between MCV and the HIF-1 pathway. While few of
the oncoviruses discussed herein have the same method of
enhancing HIF-1 levels, the end result is the same: downstream
activation of cancer-promoting genes. Although we have high-
lighted numerous studies that exemplify a link between viral
genes and HIF-1, future studies should employ quantitative meth-
ods to elucidate molecular mechanisms as present in a natural
infection. Appropriate target cell selection for respective viral
infections is important to fully understand the context of these
viral genes on HIF-1. Ultimately we require a thorough under-
standing of how intrinsic host cell HIF-1 regulation is affected by
viral genomes and their life cycles. However, given the exhaustive
evidence for HIF-1 activation by oncoviruses, HIF-1 or the viral
genes responsible for its activity represent ideal candidates for
targeted therapeutics for cancers of viral etiology.
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